Pten -null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction

Cancer Discovery

Volumn 3, Issue 8, 2013, Pages 908-921

  Curry, Natasha L ^a   Mino Kenudson, Mari ^b   Oliver, Trudy G ^d,e,h   Yilmaz, Ömer H ^b,g   Yilmaz, Vedat O ^a   Moon, Jade Y ^a   Jacks, Tyler ^d,e   Sabatini, David M ^d,e,f,g   Kalaany, Nada Y ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CELL CULTURE; CELL HETEROGENEITY; CELL PROLIFERATION; CONTROLLED STUDY; DIET RESTRICTION; ENDOPLASMIC RETICULUM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHENOTYPE; TUMOR VOLUME;

ANIMALS; CALORIC RESTRICTION; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; ONCOGENE PROTEINS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; PYROPHOSPHATASES; TUMOR CELLS, CULTURED;

EID: 84881535762     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0507     Document Type: Article

References (30)

1. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 2011; 30: 3305-16.
2. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009; 458: 725-31.
3. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
4. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
5. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95: 15587-91.
6. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
7. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62.
8. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010; 143: 711-24.
9. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-8.
10. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-25.
11. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32: 148-9.
12. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 2008; 68: 1119-27.
13. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010; 24: 837-52.
14. Keller A, Eistetter HR, Voss T, Schafer KP. The pulmonary surfactant protein C (SP-C) precursor is a type II transmembrane protein. Biochem J 1991; 277: 493-9.
15. Calnan DR, Brunet A. The FoxO code. Oncogene 2008; 27: 2276-88.
16. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13: 748-53.
17. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-15.
18. Trombetta ES, Helenius A. Glycoprotein reglucosylation and nucleotide sugar utilization in the secretory pathway: identifi cation of a nucleoside diphosphatase in the endoplasmic reticulum. EMBO J 1999; 18: 3282-92.
19. Colby TV, Koss M, Travis WD. Adenocarcinoma of the lung. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology: tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 179-201.
20. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
21. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8: 1178-84.
22. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998; 17: 1557-65.
23. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
24. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
25. Yanagi S, Kishimoto H, Kawahara K, Sasaki T, Sasaki M, Nishio M, et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 2007; 117: 2929-40.
26. Tiozzo C, De Langhe S, Yu M, Londhe VA, Carraro G, Li M, et al. Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury. Am J Respir Crit Care Med 2009; 180: 701-12.
27. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009; 4: 1064-72.
28. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab 2005; 1: 231-44.
29. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-75.
30. Wapnir IL, Wartenberg DE, Greco RS. Three dimensional staging of breast cancer. Breast Cancer Res Treat 1996; 41: 15-9.